Levetiracetam Bristol Lab (Levetiracetam)

Levetiracetam is an anticonvulsant indicated for several seizure disorders.

• Partial‑onset seizures: reduces the frequency of focal seizures and improves seizure control.
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy.
• Myoclonic seizures: decreases myoclonic jerks and associated seizure activity.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilising neuronal membranes. This interaction reduces neuronal hyper‑excitability and limits the propagation of abnormal electrical activity that underlies seizure generation.

Levetiracetam may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Fatigue: feeling unusually tired or low in energy.
• Somnolence: increased sleepiness during the day.
• Irritability: mood changes including agitation.
• Headache: mild to moderate head pain.
• Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome: rare but serious skin disorder.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Severe skin rash: widespread erythema or blistering.
• Blood dyscrasias: abnormal blood counts.
• Depression: new or worsening depressive symptoms.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal function monitoring: adjust dose in patients with impaired clearance.
• Gradual discontinuation: avoid abrupt withdrawal to reduce seizure recurrence.
• Psychiatric history: use caution in patients with depression or suicidal tendencies.
• Pregnancy considerations: safety data are limited; weigh benefits against potential risks.
• Concomitant CNS depressants: monitor for additive sedation.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Carbamazepine: may lower levetiracetam plasma levels, reducing effectiveness.
• Phenytoin: can decrease levetiracetam concentrations.
• Phenobarbital: may reduce levetiracetam exposure.
• Enzyme‑inducing antiepileptics: can increase clearance of levetiracetam.
• Oral contraceptives: levetiracetam may reduce hormonal contraceptive efficacy.

Moderate Interactions (Monitor Closely)

• Valproic acid: may increase levetiracetam levels, requiring dose adjustment.
• Other antiepileptic drugs: potential additive CNS effects.
• Alcohol: can enhance sedation and dizziness.
• CNS depressants: monitor for increased drowsiness.